Quality-Adjusted Survival in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Receiving First-Line Therapy with Panitumumab Plus Folfox Versus Folfox Alone

J. Wang, Jean‐Yves Douillard, S. Braun et al.|Annals of Oncology|2012

Cited by 0